POSTERS ASCO 2024

• Melanoma y cánceres de piel

Lenvatinib (len) plus pembrolizumab (pembro) in patients with advanced melanoma that progressed on anti–PD-(L)1 therapy: Over 4 years of follow-up from the phase 2 LEAP-004 study.

Abstract: 9559 Poster Bd #: 343